Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $534.6 million.

  • Tarsus Pharmaceuticals' Liabilities and Shareholders Equity rose 4205.71% to $534.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 3943.11%. This contributed to the annual value of $377.0 million for FY2024, which is 4199.77% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Liabilities and Shareholders Equity of $534.6 million as of Q3 2025, which was up 4205.71% from $495.0 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $534.6 million during Q3 2025, and its lowest value of $178.9 million during Q4 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $252.8 million (2022), whereas its average is $295.2 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Liabilities and Shareholders Equity surged by 10655.42% in 2021, and later crashed by 2527.45% in 2023.
  • Tarsus Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $178.9 million in 2021, then increased by 27.36% to $227.9 million in 2022, then grew by 16.51% to $265.5 million in 2023, then skyrocketed by 42.0% to $377.0 million in 2024, then soared by 41.8% to $534.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $534.6 million in Q3 2025, compared to $495.0 million in Q2 2025 and $500.8 million in Q1 2025.